Effect of Interleukin 17 and Epidermal Growth Factor 2 (FGF2) on the Biological Behavior of Endometrial Carcinoma Human Endometrial Cancer-1B Cells

Abstract

The clinical prognosis of endometrial cancer is poor. We assessed the influence of IL-17 and FGF2 on HEC-1B cells to provide evidence for the clinical prevention and treatment. HEC-1B cells were assigned into control group, IL-17 group, FGF2 group, and IL-17+FGF2 group followed by analysis of cell viability, IL-17 and FGF2 protein and mRNA content by Western Blot and RT-PCR. Under co-culture, the cell viability, migration and invasion and FGF2 level in IL-17 group, FGF2 group, and IL-17+FGF2 group were found to be significantly higher than those in control Group (P <0.05), but the apoptosis rate was significantly lower than control group. The above changes were more significant in IL-17+ FGF2 group compared to other three groups (P < 0.05). IL-17 and FGF2 treatment in HEC-1B cells can significantly promote the viability, migration and invasion of malignant tumor cells with more significant changes in the IL-17+FGF2 intervention group, suggesting these two have a synergistic effect. In conclusion, IL-17 and FGF2 exerts synergistic effect on promoting endometrial cancer cell migration and invasion, indicating that they might be novel targets for the treatment of endometrial cancer.